Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.

Law firm Kahn Swick & Foti is investigating Indivior Pharmaceuticals' proposed acquisition of Supernus Pharmaceuticals for 1.5401 Indivior common shares per Supernus share. The investigation is assessing whether the proposed consideration and process are adequate for Supernus shareholders, creating legal and execution uncertainty around the transaction.

Analysis

This is a routine post-announcement fiduciary investigation rather than evidence of a new transaction impediment; absent a filed injunction, revised consideration, or regulator action, it should not alter base-case closing odds. The relevant market signal is the SUPN/INDV exchange-ratio spread: a widening beyond normal borrow, FX/ADR, and execution costs would indicate investors are assigning a higher probability to either shareholder resistance or a renegotiation attempt.

INDV bears the strategic execution risk because a stock-funded acquisition transmits any acquirer multiple compression directly into the consideration value. Over the next 1-3 months, INDV’s ability to articulate pro forma leverage, synergy timing, and the durability of the combined CNS/addiction-treatment revenue base will matter more than litigation headlines. A sustained INDV selloff can make the implied SUPN value unattractive even if the deal technically remains intact, increasing the risk of a vote-related delay or repricing pressure.

The contrarian view is that litigation publicity may create a temporary SUPN discount without changing fundamentals, offering merger-arbitrage entry only if the annualized gross spread compensates for stock consideration volatility. The key falsifiers are a court filing seeking injunctive relief, a material decline in INDV before the shareholder vote, reduced management guidance, or disclosed regulatory review that extends closing beyond the market-implied timetable.

Key Decisions for Investors

• No directional trade on the investigation headline alone; monitor SEC filings for an actual complaint, injunction request, amended merger agreement, or changed vote timetable.
• For merger-arbitrage mandates, calculate the live ratio hedge: long 1 SUPN and short 1.5401 INDV only when the annualized gross spread exceeds 12-15% after borrow, financing, and expected stock-volatility costs; size modestly until the shareholder-vote and antitrust path are confirmed.
• Use a risk stop if INDV falls more than 15% from the hedge-entry reference without a corresponding improvement in SUPN’s implied value, as stock consideration exposes the spread to acquirer-specific multiple compression.
• Avoid naked SUPN longs as a legal-event trade. The upside from a hypothetical bump is speculative, while a broken-deal outcome would expose SUPN to standalone valuation and financing assumptions not validated by this notice.